Biofrontera AG / Key word(s): Alliance/Contract
Ad-hoc Release pursuant to Art. 17 MAR
- The agreement covers the commercialization of Ameluz(R) by Maruho in East Asia and Oceania.
- Biofrontera AG grants Maruho an exclusive license to develop and market Ameluz(R) for all indications in East Asia and Oceania. Any use of the provided technology by Maruho outside these regions is expressly prohibited. Maruho is entitled, with the consent of Biofrontera, to carry out research and development within the scope of the license. Maruho will grant to Biofrontera a free and unlimited license for the results of such research and development activities by Maruho for commercialization outside East Asia and Oceania.
- For this purpose, Maruho is to make an upfront payment to Biofrontera AG in the amount of EUR 6 million upon signing of the agreement, plus additional future payments subject to achievement of certain regulatory and sales milestones. Maruho will also make royalty payments at an initial rate of 6%, which will increase depending on sales volume and will be reduced should generic products become available in the respective countries.
- Maruho has an obligation for commercially reasonable efforts to market Ameluz(R) in all countries of the territory.
- Ameluz(R) will be supplied by Biofrontera to Maruho at cost plus 25%.
- The agreement has a term of 15 years from the start of distribution in the respective country.
On February 27, 2020, Biofrontera AG obtained an independent expert assessment of the economic feasibility of the outlined terms. The findings confirm the adequacy of the terms and conditions of the agreement.
Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen
Contact: Biofrontera AG
|Hemmelrather Weg 201|
|Phone:||+49 (0)214 87632 0|
|Fax:||+49 (0)214 87632 90|
|ISIN:||DE0006046113, NASDAQ: BFRA|
|Listed:||Regulated Market in Dusseldorf, Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Hamburg, Munich, Stuttgart, Tradegate Exchange; Nasdaq|
|EQS News ID:||988241|
|End of Announcement||DGAP News Service|